Ramsey Quantitative Systems reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 28.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,744 shares of the medical instruments supplier’s stock after selling 1,495 shares during the period. Ramsey Quantitative Systems’ holdings in West Pharmaceutical Services were worth $354,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in WST. Acrospire Investment Management LLC acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $113,000. Citigroup Inc. increased its position in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares in the last quarter. Bradley Foster & Sargent Inc. CT acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $212,000. Harfst & Associates Inc. acquired a new stake in West Pharmaceutical Services in the 1st quarter valued at about $186,000. Finally, CIBC Asset Management Inc acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $223,000. 90.57% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services, Inc. (NYSE:WST) traded up 1.15% during midday trading on Friday, reaching $95.21. 149,622 shares of the company’s stock traded hands. The stock has a 50-day moving average of $87.78 and a 200 day moving average of $89.57. West Pharmaceutical Services, Inc. has a 52-week low of $70.17 and a 52-week high of $99.91. The company has a market cap of $7.05 billion, a P/E ratio of 40.86 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $397.60 million during the quarter, compared to analysts’ expectations of $406.00 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 earnings per share. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post $2.68 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Tuesday, October 17th. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.22%.

TRADEMARK VIOLATION WARNING: “Ramsey Quantitative Systems Has $354,000 Position in West Pharmaceutical Services, Inc. (WST)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/24/ramsey-quantitative-systems-has-354000-position-in-west-pharmaceutical-services-inc-wst.html.

Several research firms have weighed in on WST. Jefferies Group LLC restated a “hold” rating and issued a $90.00 price objective on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 price objective for the company in a research report on Friday, June 9th. Finally, BidaskClub cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $98.52.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.